Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone - Avet-Loiseau, H; Soulier, J; Fermand, J-P; Yakoub-Agha, I; Attal, M; Hulin, C; Garderet, L; Belhadj, K; Dorvaux, V; Minvielle, S; Moreau, P (Leukemia, 2010)
Keywords: 631/208/1405; 631/67/1059/99; 692/699/67/1990/804; 692/700/1750; Abnormalities; Adult; Aged; Aged, 80 and over; Antineoplastic agents; Biological and medical sciences; Boronic Acids - therapeutic use; Bortezomib; Cancer Research; Chemotherapy; Chromosome Aberrations; Critical Care Medicine; Cytogenetics; Dexamethasone; Dexamethasone - administration & dosage; Dosage and administration; Drug therapy; Drug Therapy, Combination; Female; Fluorescence; Fluorescence in situ hybridization; Genetic aspects; Health aspects; Hematology; Hemoglobin; Humans; Immunodeficiencies. Immunoglobulinopathies; Immunoglobulinopathies; Immunopathology; Immunotherapy; Intensive; Internal Medicine; Laboratories; Leukemia; Male; Medical prognosis; Medical sciences; Medicine; Medicine & Public Health; Middle Aged; Multiple myeloma; Multiple Myeloma - drug therapy; Multiple Myeloma - genetics; Multiple Myeloma - mortality; Multivariate Analysis; Oncology; original-article; Patient outcomes; Patients; Pharmacology. Drug treatments; Proportional Hazards Models; Pyrazines - therapeutic use; Retrospective Studies; Steroids; Survival; Targeted cancer therapy; Thalidomide; Thalidomide - administration & dosage; Thalidomide - analogs & derivatives; Thalidomide - therapeutic use; Transplants & implants; Treatment Outcome; France; United States--US; Paris France; FISH; myeloma; lenalidomide; cytogenetics; prognosis; Antineoplastic agent; High risk; Relapse; Prognosis; Myeloma; Immunoglobulinopathy; Lymphoproliferative syndrome; Fluorescence in situ hybridization; Genetics; Advanced stage; Human; Corticosteroid; Immunopathology; Drug combination; Treatment resistance; Dexamethasone; Hematology; Lenalidomide; Steroid hormone; B cell neoplasm; Malignant hemopathy; Lymphoid neoplasm; Chemotherapy; Treatment; Cytogenetics; Cancer